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Multicentric Castleman disease (MCD) is a lymphoproliferative disorder caused by human herpesvirus 8 (HHV8)
infection HIV associated MCD (HIV-MCD) presents with various clinical symptoms. Many HIV-negative MCD patients
are often treated with anti-human interleukin-6 (IL6) receptor monoclonal antibodies (tocilizumab), and successful
results have been reported. IL-6 plays an important role in the development of both HIV-positive and HIV-negative
MCD; however, the efficacy of tocilizumab in HIV-MCD patients is unknown. We herein report the clinical and
biologic courses of two HIV-MCD patients treated with tocilizumab. In both cases, a significant and rapid clinical
improvement was observed after the first infusion. However, the treatment efficacy was not maintained for a long
period, and relapse occurred at 15 and 22 weeks, respectively. Both patients received rituximab and subsequently
achieved complete clinical remission. Our report, in addition to data presented in the literature, suggests that
tocilizumab could be an initial treatment option in patients with HIV-MCD.
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Multicentric Castleman disease (MCD) is a lymphopro-
liferative disorde, and HIV-associated MCD (HIV-MCD)
is caused by human herpesvirus 8 (HHV8) infection in
HIV-positive patients [1]. HIV-MCD presents with vari-
ous clinical symptoms, including fever, swelling of the
spleen, liver and systemic lymph nodes and abnorma-
lities in laboratory values, such as findings of anemia,
thrombocytopenia or hypergamma-globulinemia, as well
as a low albumin, or high C-reactive protein (CRP) level.
HHV8 resides latent infection and replicates in the plas-
mablasts of lymph nodes under conditions of immuno-
deficiency. Many HIV-negative MCD patients are treated
with anti-human interleukin-6 (IL6) receptor monoclonal
antibodies (tocilizumab), with successful results having
been reported [2]. IL-6 plays an important role in the de-
velopment of both HIV-positive MCD and HIV-negative
MCD; however, the efficacy of tocilizumab in HIV-MCD
patients is unknown. We herein report the results of two
HIV-MCD patients treated with tocilizumab.* Correspondence: azusanagaooo@gmail.com
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A 44-year-old male who was HIV-1 seropositive for se-
veral years and did not start treatment with combination
antiretroviral therapy (cART), with a CD4 cell count of
188 cells/μl and a viral load of 74 copies/μl, was diag-
nosed with Kaposi’s sarcoma and treated with two cycles
of liposomal doxorubicin and cART. Hepatitis C and B
were negative. Eight months after being diagnosed with
Kaposi’s sarcoma, he presented with a high fever, fatigue
and lymph nodes swelling throughout his body. Blood
tests revealed anemia (hemoglobin: 8.3 g/dl), thrombo-
cytopenia (3.3×104/μ), a low albumin level (2.3 g/dl) and
a high CRP level (10.75 mg/dl). The high fever persisted
for two weeks. A lymph node biopsy demonstrated re-
markable infiltration of polyclonal plasma cells and plas-
mablastic cells in the interfollicular areas. Lymph node
architecture was retained. Vascular proliferation was ob-
served between the follicles, with perivascular hyaliniza-
tion. The levels of HHV8 and human IL6 (hIL6: reference
normal value <4.0 pg/mL) in the blood were 460,000
copies/μl and 41.7 pg/ml, respectively. The patient was di-
agnosed with HIV-MCD and 8 mg/kg of tocilizumab wasLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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disappeared within a few hours. There were no adverse
events of tocilizumab treatment. After one week, the la-
boratory abnormalities recovered: hemoglobin 10.8 g/dl,
platelets 11.2×104/μ, albumin 3.8 g/dl and CRP 0.15 mg/dl.
The HHV8 concentration and hIL6 level in the blood
decreased to 120 copies/μl and 18.2 pg/ml, respectively,
after treatment (Figure 1, Case 1). Treatment with toci-
lizumab was continued once every two weeks, and the
patient remained symptom-free for eight cycles. How-
ever, 15 weeks after the start of treatment, symptom re-
lapse occurred, with a high fever, fatigue and lymph
nodes swelling. The CD4 count had increased from 150
to 250 cells/μl; however, at the time of relapse, the CD4
count was 109 cells/μl. Blood tests showed a hemoglobin
level of 7.7 g/dl, a platelet count of 4.3×104/μ, an al-
bumin level of 2.1 g/dl, a CRP level of 8.18 mg/dl, an
HHV8 titer of 3,400,000 copies/μl and a hIL6 level of
305 pg/ml, indicating HIV-MCD relapse. A second lymph
node biopsy showed angiofollicular hyperplasia and in-
terfollicular plasma cell infiltration. HHV8 antigens were
more strongly positive in lymphocytes than that observed
on the first biopsy. The patient received tocilizumab in-
fusions once in week for two weeks (the 15th and 16th
weeks); however, his symptoms and blood test abnorma-
lities worsened. Tocilizumab was discontinued and he re-
covered following the administration of four cycles of
rituximab treatment. He has since remained in remission
for four years.Figure 1 hIL6, HHV8 and CRP dynamic. Changes in the levels of human
C-reactive protein (CRP) in Cases 1 and 2 following the initiation of tocilizuma
the time of relapse. The gray boxes indicate the frequency of tocilizumab infuCase 2
A 45-year-old male with HIV infection, a CD4 cell count
of 328 cells/μl and an HIV RNA level of 83 copies/μl
had received cART for several years. The patient was also
infected with hepatitis C virus (genotype 1b), although
hepatitis B was negative. In 2012, he presented with a high
fever and fatigue with swollen lymph nodes throughout
his body. A blood test showed anemia (a hemoglobin level
of 6.1 g/dl), a low albumin level (2.4 g/dl), a high CRP
level (13.59 mg/dl), a low platelets count (8.7×104/μl) and
hyper gammaglobulinemia (2,993 mg/dl). He was diag-
nosed with HIV-MCD based on the findings of a lymph
node biopsy. The follicles showed varied degrees of invo-
lution and hyalinization of the germinal centers with
prominent mantle zones that intruded into the germinal
centers, completely effacing them. In the mantle zone
cells, variable numbers of plasma cells and lymphocytes
with HHV8 antigens were observed. The levels of hIL6
and HHV8 in the blood were 53.5 pg/ml and 390,000
copies/μl, respectively. The patient received 8 mg/kg of
tocilizumab 10 days after appearance of symptoms. Fol-
lowing the administration of tocilizumab, the high fever
immediately decreased. The abnormal values on the blood
examinations improved two weeks after treatment: hemo-
globin 14.8 g/dl, platelets 12.9×104/μl, albumin 4.4 g/dl
and CRP 0.07 mg/dl. The levels of HHV8 and hIL6 de-
creased to 5,100 copies/μg and 35 pg/ml, respectively,
eight weeks after treatment (Figure 1, Case 2). Six cycles
of tocilizumab were administered once every two weeksinterleukin-6 (hIL6), human herpesvirus 8 (HHV8) DNA and serum
b therapy. ● hIL6, △CRP and ■ HHV8 in the serum. ↓ The arrows indicate
sion.
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CRP level became negative (<0.3 mg/dl), and the dosing
intervals were extended in a stepwise fashion to two cycles
every three weeks then one cycle every five weeks. There
were no adverse effects of tocilizumab treatment. How-
ever, 22 weeks after the starting of tocilizumab therapy,
one week after the ninth tocilizumab infusion, a high fever,
lymph node swelling and blood test abnormalities were
detected. The levels of hIL6 and HHV8 were extremely
high, at 219 pg/mL and 97,000 copies/ul, respectively. The
CD4 count was 300–350 cells/μl, although it decreased to
164 cells/μl at recurrence. Two additional tocilizumab in-
jections within one week (the 23rd week) were ineffective.
The patient subsequently received rituximab for four cy-
cles, after which all of his symptoms and outlier values re-
covered. He has exhibited no relapse for the last year.
Discussion
In this study, infusion of tocilizumab resulted in the
rapid improvement of the patients’ symptoms with no
adverse effects, in addition to normalization of their blood
abnormalities associated with HIV-MCD. However, the
response was of short duration in both cases after the end
of therapy.
HIV-negative MCD patients treated with tocilizumab
exhibit very higher levels of hIL6 after treatment because
hIL6 receptors are blocked by IL-6 receptor antibodies
[2]. However, in the present cases, the hIL6 and HHV8
levels decreased after treatment. This suggests that HHV8
replication due to immunodeficiency was the primary
pathogenesis of HIV-MCD in these cases, resulting in a
vicious cycle of hIL6 production being blocked by the in-
hibition of IL6 signal transmission following the adminis-
tration of tocilizumab. HIV-negative MCD patients were
successfully treated with tocilizumab in two open label
trials. However, Nisimoto et al. reported that only 2/28 pa-
tients were seropositive for HHV8 [2]. The pathophysio-
logy of HIV-MCD may differ from that of HIV-negative
MCD. HHV8 encodes viral IL6 (vIL6), a homolog of hIL6.
The amino acid sequence of the vIL6 protein is 24.7%
identical to hIL6 [3]. Because vIL6 stimulates HHV 8 rep-
lication and hIL6 secretion in a direct autocrine manner
to promote the proliferation and survival of cells in which
HHV8 are produced or in a paracrine manner to induce
hIL6 in surrounding cells, it can also increase the level of
hIL6 [1,4]. Tocilizumab cannot directly inhibit vIL6 recep-
tors or vIL6 production induced by HHV8. The amount
of vIL6 production is low, and the binding affinity of vIL6
to human IL6 receptors is weak. The present cases suggest
that an increased serum concentration of hIL6 produced
by HHV8-positive cells plays a more important role in the
pathogenesis of HIV-MCD than vIL6 in the initial phase,
as tocilizumab was effective in both cases. In experiments
of mice, transfer of the vIL-6 transgene onto an IL-6deficient genetic background abrogated MCD-like pheno-
types, indicating that endogenous IL-6 is a crucial cofactor
in the natural history of the disease [4]. Moreover, with re-
spect to clinical data, Polizzotto M. et al. reported that, in
their study, the IL-6 profiles of MCD patients fell into
three distinct categories: elevation of vIL6 only (6%), ele-
vation of hIL-6 only (50%) and elevation of both hIL-6
and vIL-6 (38%). The patients with flares associated with
both elevated hIL-6 and vIL-6 levels exhibited worse
symptoms [5]. The inhibition of hIL6 by tocilizumab re-
duces the replication of HHV8 in B-cells and decreases
the hIL6 levels in the blood. An increased hIL-6 level
stimulates HHV8 replication, resulting in higher levels of
both vIL6 and hIL6. Tocilizumab may break this vicious
cycle by blocking hIL-6 at initial phase and consequently
switching off HHV8 replication in B cell. However, toci-
lizumab, by unknown mechanisms was ineffective at the
relapse during continued treatment. Because the CD4
count was low in both patients at the time of relapse in
spite of undetectable HIV RNA levels in the serum, the
occurrence of HIV-MCD flares may be dependent on
HIV-induced immunodeficiency, and controlling HIV in-
fection is a major factor in patients with HIV-MCD.
Rituximab therapy is able to suppress the symptoms
and signs of inflammation and decrease the risk of
lymphoma in patients with HIV-MCD [6-8]. Gérard L.
et al. reported that, in their studies, the three-month re-
sponse rate to rituximab was 78.3% in MCD and the
two-year MCD flare-free survival was 74.7% [7]. How-
ever, in these studies, Kaposi’s sarcoma flares were ob-
served in eight of 12 patients and four of 11 patients,
respectively [6,8]. In the present study, Kaposi’s sarcoma
reactivation was not observed under tocilizumab and ri-
tuximab therapy in Case 1.
It is not known how much or how often tocilizumab
should be administered in HIV-MCD patients or whether
combination therapy with rituximab and tocilizumab is
better than monotherapy with rituximab or ganciclovir.
Although the effects of tocilizumab have been studied
more extensively in HIV-negative patients with the refrac-
tory form of MCD, our HIV-positive patients did not re-
spond to tocilizumab in the remission phase. We propose
the use of tocilizumab treatment in patients with HIV-
positive MCD as first-line therapy. It is very impor-
tant to elucidate the precise pathophysiology of HIV
MCD in order to select appropriate therapeutic medi-
cations. Clinical studies of tocilizumab, used alone and in
combination with AZT and/or valganciclovir, are under-
way (NCT01441063) and will assist in elucidating these is-
sues. The accumulation and analysis of case reports is
required to evaluate when and how tocilizumab should
be administered with or without other drugs, including
rituximab, ganciclovir and etoposide, in patients with
HIV-MCD.
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